Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With Decreased Susceptibility to Aztreonam/Avibactam in China

被引:8
作者
Yu, Wei [1 ]
Shen, Ping [1 ]
Chen, Yunbo [1 ]
Zhou, Kai [2 ,3 ]
Chi, Xiaohui [1 ]
Xiao, Yonghong [1 ]
机构
[1] Zhejiang Univ, Sch Med,State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1,Natl Clin Res Ctr Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China
[2] Jinan Univ, Shenzhen Peoples Hosp, Shenzhen Inst Resp Dis, Clin Med Coll 2, Shenzhen, Peoples R China
[3] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen Peoples Hosp, Shenzhen, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2022年 / 12卷
关键词
carbapenem-resistant Klebsiella pneumoniae; aztreonam; avibactam; bla(KPC); membrane porin; mutation; LATIN-AMERICA; EUROPE; ASIA;
D O I
10.3389/fcimb.2022.926209
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aztreonam/avibactam (AZA), as one of the novel beta-lactamases and beta-lactamase inhibitor combinations, is considered to be a promising option for bloodstream infection (BSI) of carbapenem-resistant Klebsiella pneumoniae (CR-Kp). However, decreased susceptibility of AZA activity in Enterobacterales has been reported. The aim of this study was to identify the mechanisms of BSI CR-Kp with decreased susceptibility of AZA (minimal inhibitory concentration above 16/4 mg/L) (AZAH-Kp). Nine BSI AZAH-Kp isolates were screened from 317 CR-Kp isolates in Blood Bacterial Resistant Investigation Collaborative System (BRICS) program. Whole genome sequencing, bioinformatics analysis, and the relative expression of bla(KPC), ompK35, and ompK37 were explored for CR-Kp with decreased susceptibility to AZA. The results revealed that elevated inhibitory concentration of AZA has emerged in CR-Kp before previous clinical exposure. In addition, decreased AZA susceptibility was associated with higher KPC expression and changes in OmpK35-37.
引用
收藏
页数:5
相关论文
共 15 条
  • [1] Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia
    Biagi, M.
    Lamm, D.
    Meyer, K.
    Vialichka, A.
    Jurkovic, M.
    Patel, S.
    Mendes, R. E.
    Bulman, Z. P.
    Wenzler, E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [2] Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae
    Biagi, M.
    Wu, T.
    Lee, M.
    Patel, S.
    Butler, D.
    Wenzler, E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [3] CLSI (Clinical and Laboratory Standard Institute), 2016, Twenty-Second Informational Supplement.
  • [4] Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
    Cornely, Oliver A.
    Cisneros, Jose M.
    Torre-Cisneros, Julian
    Jesus Rodriguez-Hernandez, Maria
    Tallon-Aguilar, Luis
    Calbo, Esther
    Horcajada, Juan P.
    Queckenberg, Christian
    Zettelmeyer, Ulrike
    Arenz, Dorothee
    Rosso-Fernandez, Clara M.
    Jimenez-Jorge, Silvia
    Turner, Guy
    Raber, Susan
    O'Brien, Seamus
    Luckey, Alison
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 618 - 627
  • [5] Management of carbapenem-resistant Enterobacteriaceae infections
    Durante-Mangoni, E.
    Andini, R.
    Zampino, R.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) : 943 - 950
  • [6] Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates
    Giddins, Marla J.
    Macesic, Nenad
    Annavajhala, Medini K.
    Stump, Stephania
    Khan, Sabrina
    McConville, Thomas H.
    Mehta, Monica
    Gomez-Simmonds, Angela
    Uhlemann, Anne-Catrin
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (03)
  • [7] Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China
    Han, Renru
    Shi, Qingyu
    Wu, Shi
    Yin, Dandan
    Peng, Mingjia
    Dong, Dong
    Zheng, Yonggui
    Guo, Yan
    Zhang, Rong
    Hu, Fupin
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [8] Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
    Mendes, Rodrigo E.
    Doyle, Timothy B.
    Streit, Jennifer M.
    Arhin, Francis F.
    Sader, Helio S.
    Castanheira, Mariana
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (11) : 2833 - 2838
  • [9] In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae
    Niu, Siqiang
    Wei, Jie
    Zou, Chunhong
    Chavda, Kalyan D.
    Lv, Jingnan
    Zhang, Haifang
    Du, Hong
    Tang, Yi-Wei
    Pitout, Johann D. D.
    Bonomo, Robert A.
    Kreiswirth, Barry N.
    Chen, Liang
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 559 - 565
  • [10] Multiplex PCR for detection of acquired carbapenemase genes
    Poirel, Laurent
    Walsh, Timothy R.
    Cuvillier, Vincent
    Nordmann, Patrice
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 70 (01) : 119 - 123